title: Paclitaxel and bevacizumab in first-line treatment for HER2-negative metastatic breast cancer: single-center experience.
abstract: The aim of our analysis was to report the outcome and safety of patients treated with bevacizumab and paclitaxel as first-line treatment for HER2-negative metastatic breast cancer. Between February 2009 and August 2011, 62 consecutive patients received paclitaxel 90 mg/m(2) on days 1, 8, and 15 and bevacizumab (BV) 10 mg/kg intravenously on days 1 and 15, every 28-day cycle. After 6 cycles of combined treatment, patients were given maintenance BV every 3 weeks (15 mg/kg) until progression disease or unacceptable toxicity. At time of analysis, median overall survival was 12.3 months (range 4.6-44.8 months), progression-free survival was 8.1 months (range 2.3-33.2 months), and time to treatment failure was 8.4 months (range 2.3-33.2 months). Our results confirmed the efficacy and the acceptable toxicity profile of bevacizumab plus paclitaxel as first-line regimen for metastatic breast cancer.
authors.affiliation: Radiotherapy Unit, IFCA, University of Florence, Via di Barbano 2/A, 50129 Florence, Italy.
authors.forename: Lorenzo
authors.initials: L
authors.lastname: Livi
authors.forename: Pierluigi
authors.initials: P
authors.lastname: Bonomo
authors.forename: Icro
authors.initials: I
authors.lastname: Meattini
authors.forename: Gabriele
authors.initials: G
authors.lastname: Simontacchi
authors.forename: Daniela
authors.initials: D
authors.lastname: Greto
authors.forename: Isacco
authors.initials: I
authors.lastname: Desideri
authors.forename: Fiammetta
authors.initials: F
authors.lastname: Meacci
authors.forename: Vieri
authors.initials: V
authors.lastname: Scotti
authors.forename: Sara
authors.initials: S
authors.lastname: Cecchini
authors.forename: Jacopo
authors.initials: J
authors.lastname: Nori
authors.forename: Luis Jose
authors.initials: LJ
authors.lastname: Sanchez
authors.forename: Lorenzo
authors.initials: L
authors.lastname: Orzalesi
authors.forename: Fabiola
authors.initials: F
authors.lastname: Paiar
authors.forename: Gianpaolo
authors.initials: G
authors.lastname: Biti
mesh_terms: D000328:Adult; D000368:Aged; D061067:Antibodies, Monoclonal, Humanized / Q000008:administration & dosage / Q000009:adverse effects; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D000068258:Bevacizumab; D001943:Breast Neoplasms / Q000188:drug therapy* / Q000401:mortality / Q000473:pathology; D018572:Disease-Free Survival; D005260:Female; D006801:Humans; D008875:Middle Aged; D060787:Neoplasm Grading; D009367:Neoplasm Staging; D017239:Paclitaxel / Q000008:administration & dosage / Q000009:adverse effects; D018719:Erb-b2 Receptor Tyrosine Kinases; D016896:Treatment Outcome
chemical_list: D061067:Antibodies, Monoclonal, Humanized; D000068258:Bevacizumab; D017239:Paclitaxel; D018719:Erb-b2 Receptor Tyrosine Kinases; C508053:ERBB2 protein, human